HollisterStier Allergy, a leader in the allergenic extract industry, is delighted to announce the appointment of Kyle Ferguson as its Chief Executive Officer (CEO), effective January 22, 2024. Kyle steps into his new role with a wealth of experience, boasting over 35 years of leadership in the pharmaceutical sector, where he has been instrumental in building, launching, and expanding businesses.
Before joining HollisterStier Allergy, Kyle held a significant position at Sun Pharma as the Senior Vice President with profit and loss responsibilities over three distinct business units. In this capacity, he spearheaded numerous initiatives, including the successful launch and growth of an Immunology/Biologics branded business, while also contributing as a key member of the Executive Leadership Team.
Kyle’s career also includes pivotal roles at Janssen Pharmaceuticals, part of the Johnson & Johnson family, and Bristol-Myers Squibb, where he held both global and US domestic leadership positions. His educational background is equally impressive, with a degree in Marketing and Management from St. Francis Xavier University, complemented by attendance at various executive leadership development programs, including one at the London School of Economics.
Expressing his enthusiasm for his new role, Kyle stated, “I’m privileged to join Jubilant HollisterStier Allergy as CEO. I’ll be working with a phenomenal team dedicated to their customers and the patients they serve. Together, we will drive the company’s growth and deliver impactful treatments to those in need. I hold immense respect for the company’s rich 100-year history and am honored to be the next steward of its enduring legacy.”
Under Kyle’s leadership, HollisterStier Allergy is poised for an era of continued growth, innovation, and success.
About HollisterStier Allergy
